Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8220954 | 0.85 | HTR7 (0.46) | HTR7KDM4EALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL7577244 | 0.75 | ALDH1A1 (0.51) | HTR7ALDH1A1ADRB2 | |
| Bromide SCHEMBL11618683 | 0.74 | PTGDR2 (0.51) | HTR7KDM4EALDH1A1ADRB2ADRB1 | |
| SCHEMBL11337004 | 0.73 | ABCB1 (0.53) | KDM4EALDH1A1ABCB1 | |
| SCHEMBL8226025 | 0.73 | HTR1A (0.51) | KDM4EADRB2ADRB1ABCB1 | |
| SCHEMBL4744929 | 0.73 | TP53 (0.51) | HTR7KDM4EALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL8315378 | 0.72 | HTR1A (0.37) | SMN1; SMN2ABCB1ADRA2AADRA2BADRA2C | |
| SCHEMBL11806905 | 0.71 | ABCB1 (0.51) | ADRB2ADRB1ABCB1 | |
| SCHEMBL14076211 | 0.71 | LMNA (0.55) | ALDH1A1SMN1; SMN2ADRB2ADRB1ADRA2A | |
| SCHEMBL27377174 | 0.70 | RXRA (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | HTR7 34/4885KDM4E 2229/4885ALDH1A1 814/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | HTR7 37/4885KDM4E 2362/4885ALDH1A1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.